LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients

Xia Zou, Xiumei Chi, Yu Pan, Dongning Du, Haibo Sun, Atsushi Matsuda, Wei Li, Atsushi Kuno, Xinxin Zhang, Hisashi Narimatsu, Junqi Niu, Yan Zhang

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: A combination treatment of interferon and ribavirin is the standard and the commonly used treatment for chronic hepatitis C (CHC). Developing noninvasive tests like serum indicators that can predict treatment outcome at an early stage of therapy is beneficial for individualized treatment and management of CHC. A glyco-indicator based on the glyco-alteration of serum α1-acid glycoprotein, LecT-Hepa, was discovered by glycomics technologies as a robust indicator of liver fibrosis. Here, we investigated the clinical utility of LecT-Hepa for evaluation of treatment outcome.

Results: Firstly, ninety-seven patients with CHC were used for comparison of LecT-Hepa in serum and plasma. We found no significant difference in the concentrations of LecT-Hepa in serum and plasma. And then, 213 serum specimens from 45 patients who received 48 weeks of treatment with interferon and ribavirin were followed up for 96 weeks, and were used for evaluation of the role of LecT-Hepa. We found that LecT-Hepa might reflect the change in fibrosis regression during the treatment process. Moreover, the change of LecT-Hepa at the first 12 weeks of treatment could already predict the antiviral treatment response, which was more superior to FIB-4 index and aspartate aminotransferase-to-platelet ratio index (APRI) in this study.

Conclusions: These results provide a new perspective that serum glycoprotein could be used as a joint diagnosis indicator for estimation treatment outcome of viral hepatitis at earlier stage of therapy.

Original languageEnglish
Article number44
JournalClinical Proteomics
Issue number1
Publication statusPublished - 2014 Dec
Externally publishedYes


  • CHC
  • Glycoprotein
  • LecT-Hepa
  • Non-invasive
  • Treatment outcome

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients'. Together they form a unique fingerprint.

Cite this